Mediators of Amylin Action in Metabolic Control
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Amylin (also called islet amyloid polypeptide (IAPP)) is a pancreatic beta-cell hormone that is co-secreted with insulin in response to nutrient stimuli. The last 35 years of intensive research have shown that amylin exerts important physiological effects on metabolic control. Most importantly, amylin is a physiological control of meal-ending satiation, and it limits the rate of gastric emptying and reduces the secretion of pancreatic glucagon, in particular in postprandial states. The physiological effects of amylin and its analogs are mediated by direct brain activation, with the caudal hindbrain playing the most prominent role. The clarification of the structure of amylin receptors, consisting of the calcitonin core receptor plus receptor-activity modifying proteins, aided in the development of amylin analogs with a broad pharmacological profile. The general interest in amylin physiology and pharmacology was boosted by the finding that amylin is a sensitizer to the catabolic actions of leptin. Today, amylin derived analogs are considered to be among the most promising approaches for the pharmacotherapy against obesity. At least in conjunction with insulin, amylin analogs are also considered important treatment options in diabetic patients, so that new drugs may soon be added to the only currently approved compound pramlintide (Symlin®). This review provides a brief summary of the physiology of amylin’s mode of actions and its role in the control of the metabolism, in particular energy intake and glucose metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor
McLatchie, L. M., Fraser, N. J., Main, M. J., Wise, A., Brown, J., Thompson, N., Solari, R., Lee, M. G., & Foord, S. M. (1998) · Nature · doi:10.1038/30666 · Cited by 2,134 · cited 2×
“Further, we are not aware of studies characterizing AMY receptors with all their receptor components in the periphery since the first description of RAMPs in 1998 [42].”
BackgroundHypothalamic IKKβ/NF-κB and ER Stress Link Overnutrition to Energy Imbalance and Obesity
Zhang, X., Zhang, G., Zhang, H., Karin, M., Bai, H., & Cai, D. (2008) · Cell · doi:10.1016/j.cell.2008.07.043 · Cited by 1,350
Cooper, G. J., Willis, A. C., Clark, A., Turner, R. C., Sim, R. B., & Reid, K. B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.23.8628 · Cited by 1,299 · cited 1×
“In 1986, two independent research groups identified amylin, also known as diabetesassociated peptide (DAP) or islet amyloid polypeptide (IAPP), as the major component of pancreatic islet amyloid deposits [1,2], which had been a known pathological hallmark of type 2 diabetes (2DM) and feline diabetes since the early 20…”
BackgroundDe Souza, C. T., Araujo, E. P., Bordin, S., Ashimine, R., Zollner, R. L., Boschero, A. C., Saad, M. J. A., & Velloso, L. A. (2005) · Endocrinology · doi:10.1210/en.2004-1520 · Cited by 1,171
Islet Amyloid Polypeptide, Islet Amyloid, and Diabetes Mellitus
Westermark, P., Andersson, A., & Westermark, G. T. (2011) · Physiological Reviews · doi:10.1152/physrev.00042.2009 · Cited by 1,044 · cited 1×
“Therefore, unlike humans, primates and cats, non-transgenic rats and mice do not develop amylin amyloids and, therefore, lack this pathological hallmark of 2DM (reviewed in: [20,21]).”
BackgroundPoyner, D. R., Sexton, P. M., Marshall, I., Smith, D. M., Quirion, R., Born, W., Muff, R., Fischer, J. A., & Foord, S. M. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.233 · Cited by 804 · cited 1×
“Like other peptides of the CT family, amylin acts on class B G-protein-coupled receptors (GPCRs) [41].”
BackgroundGenetic identification of a neural circuit that suppresses appetite
Carter, M. E., Soden, M. E., Zweifel, L. S., & Palmiter, R. D. (2013) · Nature · doi:10.1038/nature12596 · Cited by 587 · cited 1×
“Interestingly, nothing is known as yet about the neurotransmitter systems necessary for amylin’s effect in the LPBN and its more rostral projection areas [84]; CGRPergic neurons, which had been suggested previously [87], do not seem to be involved [84].”
BackgroundRoth, J. D., Roland, B. L., Cole, R. L., Trevaskis, J. L., Weyer, C., Koda, J. E., Anderson, C. M., Parkes, D. G., & Baron, A. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706473105 · Cited by 436
Amylin, Calcitonin Gene-Related Peptide, Calcitonin, and Adrenomedullin: A Peptide Superfamily
Wimalawansa, S. J. (1997) · Critical Reviews™ in Neurobiology · doi:10.1615/critrevneurobiol.v11.i2-3.40 · Cited by 424
Amylin: Pharmacology, Physiology, and Clinical Potential
Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010629 · Cited by 400
Self-citationGoldfine, A. B., Mun, E. C., Devine, E., Bernier, R., Baz-Hecht, M., Jones, D. B., Schneider, B. E., Holst, J. J., & Patti, M. E. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0918 · Cited by 377
Lukinius, A., Wilander, E., Westermark, G. T., Engstr�m, U., & Westermark, P. (1989) · Diabetologia · doi:10.1007/bf00285291 · Cited by 371 · cited 1×
“Non-aggregated amylin was then shown to be present in the same secretory granules of the pancreatic beta cells as insulin [5] and was identified as a novel hormone in circulating plasma in 1989 [6].”
BackgroundEnebo, L. B., Berthelsen, K. K., Kankam, M., Lund, M. T., Rubino, D. M., Satylganova, A., & Lau, D. C. W. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00845-x · Cited by 316
Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon
Srivastava, G., & Apovian, C. (2018) · Current Obesity Reports · doi:10.1007/s13679-018-0300-4 · Cited by 232
Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes
Chapman, I., Parker, B., Doran, S., Feinle-Bisset, C., Wishart, J., Strobel, S., Wang, Y., Burns, C., Lush, C., Weyer, C., et al. (2005) · Diabetologia · doi:10.1007/s00125-005-1732-4 · Cited by 205
Vilarrasa, N., Goday, A., Rubio, M. A., Caixàs, A., Pellitero, S., Ciudin, A., Calañas, A., Botella, J. I., Bretón, I., Morales, M. J., et al. (2016) · Obesity Facts · doi:10.1159/000442764 · Cited by 197
Hartter, E., Svoboda, T., Ludvik, B., Schuller, M., Lell, B., Kuenburg, E., Brunnbauer, M., Woloszczuk, W., & Prager, R. (1991) · Diabetologia · doi:10.1007/bf00404025 · Cited by 191
Aronne, L., Fujioka, K., Aroda, V., Chen, K., Halseth, A., Kesty, N. C., Burns, C., Lush, C. W., & Weyer, C. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2003 · Cited by 178
Christoffersen, B. Ø., Sanchez‐Delgado, G., John, L. M., Ryan, D. H., Raun, K., & Ravussin, E. (2022) · Obesity · doi:10.1002/oby.23374 · Cited by 142
Boyle, C. N., Lutz, T. A., & Le Foll, C. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2017.11.009 · Cited by 142
Self-citationInfusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM
Kong, M.-F., King, P., Macdonald, I. A., Stubbs, T. A., Perkins, A. C., Blackshaw, P. E., Moyses, C., & Tattersall, R. B. (1997) · Diabetologia · doi:10.1007/s001250050646 · Cited by 131
Development of Cagrilintide, a Long-Acting Amylin Analogue
Kruse, T., Hansen, J. L., Dahl, K., Schäffer, L., Sensfuss, U., Poulsen, C., Schlein, M., Hansen, A. M. K., Jeppesen, C. B., Dornonville de la Cour, C., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00565 · Cited by 129
Fineman, M. S., Koda, J. E., Shen, L. Z., Strobel, S. A., Maggs, D. G., Weyer, C., & Kolterman, O. G. (2002) · Metabolism · doi:10.1053/meta.2002.32022 · Cited by 129
Cheng, W., Gonzalez, I., Pan, W., Tsang, A. H., Adams, J., Ndoka, E., Gordian, D., Khoury, B., Roelofs, K., Evers, S. S., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.12.012 · Cited by 123 · cited 3×
“Collectively, the AP lesioning data and other data indicate that the amylin-induced signal seems to be transmitted via the NTS, the LPBN, and the central nucleus of the amygdala and possibly other higher brain centers [76,82–84] (reviewed in [14,44,65]).”
BackgroundEnoki, S., Mitsukawa, T., Takemura, J., Nakazato, M., Aburaya, J., Toshimori, H., & Matsukara, S. (1992) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(92)90074-2 · Cited by 118
Riddle, M., Frias, J., Zhang, B., Maier, H., Brown, C., Lutz, K., & Kolterman, O. (2007) · Diabetes Care · doi:10.2337/dc07-0589 · Cited by 116
Wang, M.-Y., Yan, H., Shi, Z., Evans, M. R., Yu, X., Lee, Y., Chen, S., Williams, A., Philippe, J., Roth, M. G., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424934112 · Cited by 112
Secretion of islet amyloid polypeptide in response to glucose
Kanatsuka, A., Makino, H., Ohsawa, H., Tokuyama, Y., Yamaguchi, T., Yoshida, S., & Adachi, M. (1989) · FEBS Letters · doi:10.1016/0014-5793(89)81527-3 · Cited by 107
Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes
Ryan, G., Jobe, L., & Briscoe, T. (2008) · Drug Design, Development and Therapy · doi:10.2147/dddt.s3225 · Cited by 98
Decrease of Stimulated Amylin Release Precedes Impairment of Insulin Secretion in Type II Diabetes
Ludvik, B., Lell, B., Hartter, E., Schnack, C., & Prager, R. (1991) · Diabetes · doi:10.2337/diab.40.12.1615 · Cited by 82
Amylin as a Future Obesity Treatment
Dehestani, B., Stratford, N. R., & Roux, C. W. L. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes21071 · Cited by 72 · cited 1×
“Studies of the exact mechanism of action of this and other long acting amylin analogs are ongoing [8,63,218,221,222,224,225] and at least some of the effects seem to be mediated by the necessary interaction with specific amylin receptor subtypes [218,225].”
BackgroundBoccia, L., Gamakharia, S., Coester, B., Whiting, L., Lutz, T. A., & Le Foll, C. (2020) · Peptides · doi:10.1016/j.peptides.2020.170366 · Cited by 70
Self-citationCoordinate Regulation of Amylin and Insulin Expression in Response to Hypoglycemia and Fasting
Alam, T., Chen, L., Ogawa, A., Leffert, J. D., Unger, R. H., & Luskey, K. L. (1992) · Diabetes · doi:10.2337/diab.41.4.508 · Cited by 41
Cagrilintide plus semaglutide for obesity management
Becerril, S., & Frühbeck, G. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00944-2 · Cited by 38
Zakariassen, H. L., John, L. M., & Lutz, T. A. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13427 · Cited by 37
Self-citationLarsen, A. T., Gydesen, S., Sonne, N., Karsdal, M. A., & Henriksen, K. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-020-00678-2 · Cited by 33
Mulder, H., Ahrén, B., & Sundler, F. (1996) · Diabetologia · doi:10.1007/bf00418536 · Cited by 31
Cited by
Medications for Obesity: A Review
Gudzune, K. A., & Kushner, R. F. (2024) · JAMA · doi:10.1001/jama.2024.10816 · Cited by 263
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
“Because of these actions, amylin was, with several amino acid substitutions, developed into an antidiabetic agent, pramlintide, which was approved for diabetes treatment 177 .”
Role of diet and exercise in aging, Alzheimer’s disease, and other chronic diseases
Khemka, S., Reddy, A., Garcia, R. I., Jacobs, M., Reddy, R. P., Roghani, A. K., Pattoor, V., Basu, T., Sehar, U., & Reddy, P. H. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102091 · Cited by 88
Glucagon, from past to present: a century of intensive research and controversies
Scheen, A. J., & Lefèbvre, P. J. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00349-7 · Cited by 44
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Metadata
- Authors
- Boyle, C. N., Zheng, Y., & Lutz, T. A.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2022-04-15
- Volume
- 11
- Issue
- 8
- Pages
- 2207
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W4224138107
- Cited by
- 67
- References
- 37
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.